The article, published in the Journal of Clinical Research & Bioethics, analyzed 22 clinical studies of bupivacaine liposome injectable suspension, including phase III clinical trials and post-market studies and compared them with a medical review of the new drug application from the U.S. Food and Drug Administration.
Access the article here.
More articles on spine:
Can risk sharing work? The realities of reducing low-value spine care
Pedicle subtraction osteotomy revision — 5 things to know
D Magazine honors Spine Team Texas physicians
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
